Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab in DLBCL Post-CAR T
NCT06552572Phase 2Active, not recruiting
- Sponsor
- Samsung Medical Center
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Samsung Medical Center. Started Nov 2024; status: active, not recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06552572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06552572.